NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $532,963 | +589.8% | 36,256 | +268.8% | 0.00% | +200.0% |
Q3 2023 | $77,264 | -81.8% | 9,830 | -76.9% | 0.00% | -66.7% |
Q2 2023 | $425,098 | +93.9% | 42,552 | +72.4% | 0.00% | +200.0% |
Q1 2023 | $219,236 | -87.2% | 24,689 | -81.3% | 0.00% | -90.0% |
Q3 2022 | $1,719,000 | +97.6% | 131,919 | +92.1% | 0.01% | +100.0% |
Q2 2022 | $870,000 | +4.2% | 68,684 | +15.3% | 0.01% | -28.6% |
Q1 2022 | $835,000 | +92.0% | 59,581 | +296.8% | 0.01% | +75.0% |
Q4 2021 | $435,000 | +29.5% | 15,014 | +18.6% | 0.00% | 0.0% |
Q2 2021 | $336,000 | +31.8% | 12,663 | +54.4% | 0.00% | +33.3% |
Q1 2021 | $255,000 | – | 8,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP III, LLC | 3,422,549 | $90,800,000 | 15.85% |
Ponoi II Management, LLC | 686,274 | $18,207,000 | 14.76% |
Ponoi Management, LLC | 686,274 | $18,207,000 | 10.12% |
Foresite Capital Management V, LLC | 451,522 | $11,979,000 | 4.71% |
Foresite Capital Management IV, LLC | 1,205,798 | $31,990,000 | 4.32% |
Bain Capital Life Sciences Investors, LLC | 1,284,314 | $34,073,000 | 2.23% |
EcoR1 Capital, LLC | 1,967,950 | $52,210,000 | 1.95% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $15,155,000 | 1.93% |
DAFNA Capital Management LLC | 306,320 | $8,127,000 | 1.70% |
Euclidean Capital LLC | 154,426 | $4,097,000 | 1.33% |